Latest Headlines

Latest Headlines

Curis snags $30M loan, grabs early-stage cancer drug from Genentech

And Curis immediately spent a big chunk of that to in-license an experimental cancer therapy from its colleagues at Genentech, flipping the usual order of deal-making as the little biotech paid the giant Roche subsidiary a small upfront to gain development rights.

UPDATED: Roche/Genentech drug beats back treatment-resistant breast cancer cells

A skin cancer drug developed by Roche/Genentech appears to beat back breast cancer cells resistant to tamoxifen, a standard course of treatment, researchers from Ohio have discovered.

Roche rushes new cancer drug to regulators on Ph2 data

When Roche tried to gain an approval to use T-DM1 against breast cancer based on mid-stage results from a single-arm study, the FDA sent its regulatory team packing--refusing to even review the

Roche preps vismodegib app with "profound" efficacy data

Armed with positive data from a pivotal Phase II trial, Lexington, MA-based Curis is waiting for its partner Roche to begin its long-awaited pitch to gain FDA approval for a new treatment for

Roche preps vismodegib app after Ph2 skin cancer success

Roche and Genentech have posted a fresh set of promising mid-stage data on vismodegib, a cancer drug it's collaborating on with Lexington, MA-based Curis. In what investigators describe as a pivotal

Roche tees up new app on promising Ph2 cancer drug

Lexington, MA-based Curis ($CRIS) is eagerly spreading the news that its partners at Roche/Genentech have wrapped a positive mid-stage trial for an experimental new treatment for advanced basal cell